Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01901809 · ClinicalTrials.gov registry record · Phase 4
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
A Phase 4 study of Heart Failure, Diastolic, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT01901809: Completed Phase 4 study of Heart Failure, Diastolic, sponsored by Johns Hopkins University.
NCT01901809 is a Phase 4 study of Heart Failure, Diastolic that has completed, run by Johns Hopkins University. The registered enrollment target is 90 participants, below the 314-participant average among 14 other Heart Failure, Diastolic trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01901809, a Phase 4 study of Heart Failure, Diastolic, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with heart failure with reduced ejection fraction (HFREF). Patients with HFPEF are often preload dependent and despite admission to the hospital for acute decompensated heart failure (ADHF), are typically difficult to diurese due to the development of acute kidney injury. No studies have been performed evaluating treatment strategies for these patients. The investigators hypothesize that changing the method of diuresis and/or the addition of low-dose dopamine for the treatment of ADHF in patients with HFPEF will reduce renal injury, resulting in a shorter length of stay, and decrease hospital readmissions over the ensuing year. This trial will randomize patients to either bolus or continuous infusion furosemide and then to either dopamine or no dopamine. The primary endpoint will be renal function at 72 hours as measured by change in Glomerular Filtration Rate (GFR). Secondary endpoints for readmission, functional capacity, quality of life, and amount of diuresis will also be collected.
Primary Outcome
Percent change in serum creatinine from randomization to 72 hrs from treatment protocol initiation.
Conditions Studied
Interventions
- DRUG Dopamine
- DRUG Furosemide
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-05 |
| Phase | Phase 4 |
What the finished NCT01901809 record still lists
NCT01901809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 314-participant average among 14 other Heart Failure, Diastolic trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Heart Failure, Diastolic appearing as the primary indexed condition, and to 2 interventions - of which Dopamine is the first listed.
NCT01901809 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01901809 about?
NCT01901809 is a clinical study titled "Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction". Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with heart failure with reduced ejection fraction (HFREF). Patients with HFP...
What is the current status of trial NCT01901809?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2013-08. Estimated completion is 2018-05.
What conditions does trial NCT01901809 study?
This clinical trial studies the following conditions: Heart Failure, Diastolic.
What interventions are being tested in trial NCT01901809?
The interventions under investigation include: Dopamine (DRUG), Furosemide (DRUG).
Who is sponsoring clinical trial NCT01901809?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01901809 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Diastolic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01901809's enrollment target sits among peer trials
90 7th of 14 higher than 8 of 14 other Heart Failure, Diastolic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure, Diastolic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
COMPLETED · Phase 4
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Assessment of Left Ventricular Filling Pressure by Applying Artificial Intelligence Algorithms to Left Atrial Speckle-tracking Echocardiography
RECRUITING
-
Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status
RECRUITING
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia